Radioiodine-Refractory Differentiated Thyroid Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Radioiodine-Refractory Differentiated Thyroid Cancer Market Outlook

Thelansis’s “Radioiodine-Refractory Differentiated Thyroid Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Radioiodine-Refractory Differentiated Thyroid Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Radioiodine-Refractory Differentiated Thyroid Cancer Overview

Radioactive iodine I-131 (RAI) treatment is the primary systemic therapy for advanced disease (5). It frequently leads to a cure in young patients with small metastases arising from well-differentiated thyroid cancer, particularly those exhibiting high RAI uptake in neoplastic foci. This subgroup constitutes approximately one-third of advanced thyroid cancer patients. However, in the remaining two-thirds of advanced cases, achieving a cure is a rare occurrence. These patients will eventually be classified as refractory. RAI is a pivotal component of standard adjuvant treatment for individuals with high-risk differentiated thyroid cancer (DTC). Nevertheless, 5% to 15% of DTC cases and a striking 50% of metastatic DTC cases exhibit refractoriness to RAI treatment. Those diagnosed with RAI-refractory (RAI-R) thyroid cancer face a grim prognosis, with 5-year disease-specific survival rates ranging from 60% to 70%. The outlook is even bleaker for those with RAI-R metastatic thyroid cancer, who exhibit a mere 10% 10-year survival rate. RAI refractoriness is most commonly associated with the loss of thyroid differentiation features. A clear indicator of dedifferentiation is the dysfunction of the Na/I symporter (NIS). Standard protocols for identifying recurrent and metastatic DTC following total/near total thyroidectomy and RAI therapy involve serum thyroglobulin (Tg) tests in conjunction with RAI whole body scans (WBS).

• According to Thelansis disease modeling data, literature reviews, surveys, and registry analyses, 8% to 17% of thyroid cancer (TC) patients develop distant metastases, with one-third becoming radioiodine-refractory (RAIR).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: